Figure 3From: Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study Local tolerability of injections during 12-week study period (safety population, n = 106).Back to article page